Combating cervical cancer in developing countries through vaccination

18 women die everyday of cervical cancer in Bangladesh

The World Health Organisation (WHO) has awarded pre-qualification to GlaxoSmithKline Biologicals’ cervical cancer vaccine Cerverix — says a recent press release of the company.

Cervical cancer affects more often and more aggressively in resource poor countries due to the lack of screening service and high prevalence of other serious health conditions. This certification was important for UN agencies and the Global Alliance for Vaccine and Immunisation (GAVI) to purchase the vaccine in partnership with these countries.

According to WHO, 13,000 women die every year or 18 women die everyday of cervical cancer in Bangladesh.

The vaccine is available in Bangladesh since February 2009. The vaccine has 3 doses which can be administered in women 10-45 years of age.

The company recently received an extended WHO prequalification for another crucial vaccine, Rotarix — opening the door to making rotavirus vaccines available to children worldwide to combat diarrhoea.

Source: The Daily Star, August 15, 2009